The pathophysiology of thrombotic thrombocytopenic purpura (TTP) is not well understood. Recent studies have described a platelet aggregating factor which has been characterized as a calcium-dependent cysteine protease (calpain) in patients with TTP. A type of TTP, sometimes called secondary TTP, has been associated with bone marrow transplantation (BMT). However, unlike primary adult TTP, BMT-TTP has important differences and often does not respond well to plasma exchange. We describe the measurement of calpain activity in a group of BMT patients (with and without the clinical syndrome of transplant-associated TTP). Calpain was measured using a functional assay ( 14 Cserotonin platelet release with inhibition by the cysteine protease inhibitor, leupeptin) in the sera of patients following autologous (auto) or allogeneic (allo) BMT. We also independently diagnosed and graded the BMT-TTP on the day of blood sampling using a scale that related to the percentage schistocytes and lactic dehydrogenase level. Calpain activity was detected in 1/8 (13%) grade 0-1 (6 auto, 2 allo); 6/16 (38%) grade 2 (3 auto, 13 allo) 9/16 (56%) grade 3 (2 auto, 14 allo) and 8/8 (100%) grade 4 BMT-TTP. Pre-BMT samples were tested in 10 allo-BMT patients who had positive calpain results post-BMT. One patient gave positive results before the transplant. This patient developed grade 4 BMT-TTP (day 24 post-BMT) and died despite apheresis. Positive calpain results were highly associated with neurologic symptoms, P Ͻ 0.001. Nineteen of 24 (79%) patients with positive results had neurologic symptoms compared to three of 21 (14%) patients with negative results. In conclusion, calpain was detected in half of the BMT patients with mild to moderate BMT-TTP (grades 2-3) and was uniformly found in those with severe (grade 4) BMT-TTP. Typically the calpain activity develops as TTP complicates the transplant process. It is unknown whether calpain contributes to the pathogenesis of this disorder, or is a secondary event.
Thrombotic thrombocytopenic purpura (TTP) is an uncommon but potentially life-threatening disorder, characterized by microangiopathic hemolytic anemia and destructive thrombocytopenia. 1 Other clinical sequelae include ischemic neurologic changes, fever and renal impairment. 1 Von Willebrand Factor (vWF)-rich platelet thrombi have been postulated to contribute to the disease. 2, 3 For many years a platelet aggregating factor has been suspected to be important pathogenically in TTP.
1-3 Different laboratories have described various platelet aggregating factors including calpain (calcium-dependent cysteine protease), 4 -6 a lysosomal cathepsin 7 and a 37 kDa platelet aggregating factor. 8 Clinical and laboratory observations have led us to postulate that calpain is important in the pathogenesis of TTP. [4] [5] [6] An unusual and particularly severe form of TTP can complicate bone marrow transplantation. [9] [10] [11] [12] [13] [14] This variant of TTP can be mild and self-limited but is often rapidly fulminant. 9, 11 Unlike more typical forms of TTP, BMT-TTP tends not to respond to plasma exchange. 11, 12, 14 In this report, we describe the serological investigation of a group of patients with BMT-TTP. We found that the majority of BMT-TTP patients had detectable levels of calpain activity in their blood during their acute TTP illness and the presence of calpain corresponded with its severity.
Materials and methods

Patient and control samples
Fifty-eight serum samples were obtained from 46 bone marrow transplant patients (11 auto; 35 allo) at the Adult Bone Marrow Transplant Program at the Western Pennsylvania Hospital. These patients had undergone bone marrow transplantation for a variety of malignant or hematologic diseases. Of the allo-BMT patients, the type of allo-BMT consisted of 20 allo-identical, four allo-non identical and 11 matched unrelated donor transplants. Several preparative regimens were used based upon the underlying hematologic/malignant disorder for which the bone marrow transplant was being performed. Oral busulfan (BU) 4 mg/kg/day for 4 days followed by intravenous cyclophosphamide (CY) 60 mg/kg by a 1-h infusion for 2 days was used in patients with myeloid leukemias. Patients with lymphomas were conditioned with CY 50 mg/kg/day for 2-4 days followed by 300 cGy total body irradiation (TBI) daily over 4 days. In general, Cy was given for only 2 days in the patients receiving matched unrelated donor marrow transplants. Patients with breast carcinoma were conditioned with carboplatin 200 mg/m 2 by continuous intravenous infusion (c.i.v.) over 4 h, thiotepa 125 mg/m 2 c.i.v. ϫ 4 days, and by Cy 500 mg/m 2 c.i.v. over 4 days. These patients were either participants in a prospective study of BMT-TTP, or had been identified with grade 3-4 BMT-TTP. The day of the sample collection, the patients had the grade of BMT-TTP (see subsequent section) determined by measurement of percentage fragmented cells and lactic dehydrogenase level. The research protocol was approved by the Institutional Review Board of the Western Pennsylvania Hospital. All patients gave written informed consent for these studies. Serum was also obtained from healthy laboratory volunteers (seven males and seven females). Blood was allowed to clot at room temperature. The samples were centrifuged and the serum removed and frozen at Ϫ70°C. Samples were shipped frozen on dry ice to Hamilton, Canada for the calpain assay.
Determination of fragmented erythrocytes
A single observer counted 500 red blood cells on coded blood films. The percent of fragmented red cells was then calculated as described. 9 
Grading system for BMT-TTP
We developed a grading system that related to the degree of red cell hemolysis and/or tissue damage as measured by the lactic dehydrogenase level (LDH) and percentage fragmented cells. 9 We did not include the severity of thrombocytopenia in the grading system because BMT patients typically are thrombocytopenic. This system was designed to reflect TTP ranging from no evidence, to subclinical (increased schistocytes alone) to clinical TTP of varying severity ( Table 1 ). All patients with clinical BMT-TTP had elevated LDH levels in association with elevated percentages of fragmented red cells.
Functional measurement of calpain (
C-serotonin release)
The ability of patient or control sera to release radiolabelled serotonin from normal platelets was tested as described. 5 Platelets from healthy donors were radiolabeled with 14 C- /l) were mixed with 20 l of the test serum. After a 30-min incubation at room temperature, the reaction was stopped by the addition of 100 l of 10 mmol/l EDTA in phosphate-buffered saline. The test mixtures were centrifuged at 4500 g ϫ 5 min and the 14 C-serotonin released into the supernatant was measured. Results were expressed as the amount of 14 C-serotonin release compared to the total amount of 14 C-serotonin present and expressed as a percentage of the total. Parallel studies were performed with added leupeptin (1 m/l). Leupeptin is a cysteine protease inhibitor and was used to confirm that the increased 14 Cserotonin release was due to calpain activity in the patients' sera.
Statistics
The Kruskal-Wallis ANOVA by ranks test was used to compare clinical parameters in the independent patient groups using Stat-Soft, version 5.0 (Tulsa, OK, USA). Chisquare analysis was used to compare demographic features of the independent BMT-TTP groups and calpain assay results. A P value Ͻ0.05 was considered to be significant. Table 2 is a summary of the clinical information on the patients with different grades of BMT-TTP in this study. Data are shown as median (quartiles) for the different grades. Eight patients (6 auto and 2 allo) had grade 0-1, 16 patients (3 auto and 13 allo) had grade 2, 16 patients (2 auto and 14 allo) had grade 3 and eight allo-BMT patients had grade 4 BMT-TTP. There were no significant differences in the bone marrow transplant day in any of the grades. Patients in each grade level had significantly increased levels of LDH and percentage fragmented cells, P Ͻ 0.05. By contrast, grades 2, 3 and 4, had higher plasma creatinine levels than grades 0-1. Bilirubin levels were higher in grade 2 compared with grades 0-1 and in grade 4 compared with grade 3 BMT-TTP, P Ͻ 0.05. Neurologic changes were more common (18/24 (75%)) in grades 3-4 compared to (4/24 (17%)) in grades 0-2 BMT-TTP, P Ͻ 0.001. None of the patients with grade 0-2 BMT-TTP had graft-versus-host disease, two of 14 patients with grade 3 BMT-TTP had acute GVHD. One patient had grade III GVHD and one had grade IV GVHD. By contrast, five of seven patients with grade 4 BMT-TTP had evidence of graft-versus-host disease (2 grade III, 2 grade IV, and 1 extensive chronic graft-versus-host disease).
Results
Detection of calpain activity in BMT-TTP
The mean Ϯ s.d. percentage serotonin release from serum obtained from 14 laboratory controls was 6.6 Ϯ 5.6 in the absence of leupeptin. Percentage platelet 14 C-serotonin release in the presence of leupeptin was 2.8 Ϯ 3.2. For analysis, positive calpain assay results were defined as results higher than 3 s.d. above the mean of control samples, with complete inhibition in the presence of leupeptin.
One of eight patients (6 auto, 2 allo) with grades 0-1 (no evidence or subclinical) BMT-TTP had calpain activity detected (see Table 3 ). Serum from six patients (1 auto, 5 allo) with grade 2 BMT-TTP had positive tests for calpain (mean release = 77.8% Ϯ 15.3%) that was completely inhibited by leupeptin. One patient (patient No. 24) had Table 3 Calpain functional assay BMT-TTP grade 0-2 BMT-TTP = bone marrow transplant thrombotic thrombocytopenic purpura; neat = serum alone; ϩ leupeptin = serum in the presence of a cysteine protease inhibitor, leupeptin; Auto = autologous; Allo = allogeneic.
only partial inhibition with leupeptin (Table 3) . Therefore, evidence for calpain activity was present in six of 16 (38%) of patients with clinical grade 2 TTP following bone marrow transplantation. Calpain activity was detected in the serum of 9/16 (56%) of patients (auto 2, allo 14) with grade 3 BMT-TTP (mean release = 80.2% Ϯ 19.9%) as shown in Table 4 . Serum from an additional two patients (patients Nos 15 and 38) Table 4 Calpain functional assay BMT-TTP grade 3-4 BMT-TTP = bone marrow transplant thrombotic thrombocytopenic purpura; neat = serum alone; ϩ leupeptin = serum in the presence of a cysteine protease inhibitor, leupeptin; Auto = autologous; Allo = allogeneic.
caused serotonin release, but this activity was only partially inhibited by leupeptin. All eight allo-BMT patients with grade 4 BMT-TTP (Table 4) had evidence of functional calpain activity (mean release = 79.4% Ϯ 13.9%); this activity was again inhibited by leupeptin (mean release = 4.0% Ϯ 3.1%). Serum was available from the day of admission before the transplant from 10 allo-BMT patients who had positive calpain functional assays following transplantation. One patient with chronic myelogenous leukemia (CML) had calpain activity detected in the serum before transplant. This was an atypical finding as we have not found elevated calpain in CML. This patient had no evidence of thrombotic microangiopathy on admission. However, he died of grade 4 BMT-TTP (day 45 following bone marrow transplant) despite apheresis.
Relationship of calpain activity with the clinical outcome
Positive calpain assay results were more common in allo-BMT (22/34 (65%)) than in auto-BMT (2/11 (18%)), P Ͻ 0.01, (see Table 5 ). Bone marrow transplant days were similar. There was a significantly higher number of fragmented cells and a higher association of neurologic changes in the calpain positive BMT patients, P Ͻ 0.001. Percentage fragmented cells expressed as median (quartiles) were 6.0 (3.9-10.3) in those with positive calpain results compared to 2.8 (1.8-4.4) in those with negative calpain assays. Seventy-nine percent (19/24) of patients with calpain activity had neurologic abnormalities compared to 14% (3/21) without calpain activity, Chi-square = 18.868. The neurologic changes varied. They consisted of seizures Table 5 Calpain function assay results (post-BMT) clinical presentation
Calpain (Ϫ)
Calpain ( (attributed to cyclosporin), coma, psychosis, altered mentation, dysarthria, single and multiple peripheral neuropathies, and transient hemiplegia and paraplegia. The other clinical parameters, LDH, creatinine and bilirubin levels were also significantly higher in those with calpain activity, P Ͻ 0.05.
Discussion
A syndrome of thrombotic thrombocytopenic purpura (TTP) can complicate bone marrow transplantation. [9] [10] [11] [12] [13] [14] Unlike primary TTP, 15 the TTP of BMT does not respond well to plasma exchange and is often fatal irrespective of any therapeutic intervention. 9, 12, 14 The pathophysiology of this bone marrow transplant associated disorder is not well understood and has been linked to graft-versus-host disease 9, 10, 14 or certain drugs, such as cyclosporin. 9, 10, 13 The purpose of the current study was to investigate whether BMT patients with TTP had functional calpain present in their serum. The rationale for these studies was that calpain has been observed in patients with classical TTP [3] [4] [5] [6] but not in other seriously ill hospitalized patients including patients with leukemia. Calpain is a calciumdependent protease that is present ubiquitously in human tissues and cells and in high concentrations within platelets. Calpain is bound to platelet microparticles in patients with acute TTP, 5 suggesting that another initiating event may promote its release from platelets. We have postulated that calpain participates in the pathogenesis of TTP by simultaneously activating platelets and partially proteolyzing von Willebrand factor rendering it very platelet reactive. 16, 17 The vWF binds to platelets forming platelet thrombi, which contribute to the thrombotic microvascular events that characterize TTP. Although calpain contributes to TTP, it is thought to be one of a cascade of events which results in a spectrum of symptoms. This suggests that anti-calpain agents alone will not be sufficient to manage this disorder.
Our study indicates that calpain is also detectable in patients with the TTP-like syndrome that can complicate BMT. The likelihood of detecting calpain is related to the severity of the post-transplant TTP and may be related to apoptosis. 18 The activity develops post-transplant as calpain is not present pre-transplant in most patients. Calpain is detectable in both primary TTP and the secondary TTP associated with BMT and may contribute to the pathogenesis of both disorders. The reason for poor treatment results with apheresis in BMT-TTP is unclear and suggests that other factors or initiating events occur in BMT-TTP making the disorder difficult to reverse. 
